BR9912117A - Uso de estimulador de captação de glicose para reduzir a apoptose - Google Patents

Uso de estimulador de captação de glicose para reduzir a apoptose

Info

Publication number
BR9912117A
BR9912117A BR9912117-4A BR9912117A BR9912117A BR 9912117 A BR9912117 A BR 9912117A BR 9912117 A BR9912117 A BR 9912117A BR 9912117 A BR9912117 A BR 9912117A
Authority
BR
Brazil
Prior art keywords
stimulator
glucose uptake
human
reduce
cells
Prior art date
Application number
BR9912117-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc
Publication of BR9912117A publication Critical patent/BR9912117A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9912117-4A 1998-07-21 1999-07-21 Uso de estimulador de captação de glicose para reduzir a apoptose BR9912117A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
BR9912117A true BR9912117A (pt) 2001-04-10

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912117-4A BR9912117A (pt) 1998-07-21 1999-07-21 Uso de estimulador de captação de glicose para reduzir a apoptose

Country Status (25)

Country Link
EP (2) EP1516617A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002521326A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20010079551A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1310620A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2001002036A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE288746T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU5053799A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG105250A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9912117A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2338211A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69923687T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1098639T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA200100165A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2237929T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0103199A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID26986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL140664A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20010292L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11579A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL345627A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1098639E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1098639T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK1012001A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200100207T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000004890A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073600A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
WO1998010760A1 (fr) * 1996-09-12 1998-03-19 Sankyo Company, Limited Potentialisateur d'activite de glutathione-reductase contenant de la troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
ATE325607T1 (de) * 1997-11-19 2006-06-15 Takeda Pharmaceutical Aptoptoseinhibitoren
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
EP1516617A2 (en) 2005-03-23
TR200100207T2 (tr) 2001-05-21
HUP0103199A2 (hu) 2002-05-29
DE69923687D1 (de) 2005-03-17
NO20010292D0 (no) 2001-01-18
NO20010292L (no) 2001-03-08
SK1012001A3 (en) 2001-08-06
DE69923687T2 (de) 2006-04-06
ID26986A (id) 2001-02-22
PT1098639E (pt) 2005-06-30
EP1098639B1 (en) 2005-02-09
BG105250A (en) 2001-11-30
EA200100165A1 (ru) 2001-08-27
AU5053799A (en) 2000-02-14
ES2237929T3 (es) 2005-08-01
AP2001002036A0 (en) 2001-03-31
SI1098639T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-08-31
ATE288746T1 (de) 2005-02-15
EP1098639A1 (en) 2001-05-16
OA11579A (en) 2004-06-01
PL345627A1 (en) 2002-01-02
DK1098639T3 (da) 2005-06-13
IL140664A0 (en) 2002-02-10
CN1310620A (zh) 2001-08-29
CA2338211A1 (en) 2000-02-03
JP2002521326A (ja) 2002-07-16
WO2000004890A1 (en) 2000-02-03
HK1037865A1 (en) 2002-02-22
HUP0103199A3 (en) 2002-08-28
KR20010079551A (ko) 2001-08-22

Similar Documents

Publication Publication Date Title
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
DE69932414D1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
WO2001041707A3 (en) Modulation of in vivo glutamine and glycine levels in the treatment of autism
NO985232D0 (no) Androstenderivater
EA200101089A1 (ru) Новый способ лечения
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DK0998287T3 (da) Anvendelse af levobupivacain
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
MA26777A1 (fr) Inhibiteurs d'aminotransferase dependante d'aminoacide en chaine ramifiee et leur usage dans le traitement de la retinopathie diabetique.
NO870772L (no) Vevplasminogenaktivator for normale humane tykktarmceller.
DK1083929T3 (da) Anvendelse af anabolske stoffer
FR2772622B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite configurable
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
RS52011B (sr) Nova primena derivata taksoida
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
BR9912117A (pt) Uso de estimulador de captação de glicose para reduzir a apoptose
PT1058544E (pt) Inibicao da actividade do tnf
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
FR2749514B1 (fr) Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1919 DE 16/10/2007.